Aristo Pharma
This sponsor has funded 2 studies across 13 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 12171 | Ongoing | Retrospective Cohort Study on the Risk of Venous Thromboembolism with the use of combined oral contraceptives containing Chlormadinone... | No | No |
| 33796 | Ongoing | A pregnancy exposure registry study to assess clinical follow-up and outcomes of pregnancies exposed to ulipristal acetate 30 mg. | Yes | No |
PAS by Risk Management Plan (RMP) requirement
Aristo Pharma
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Aristo Pharma
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Aristo Pharma
13 Study countries specified are the following:
- Austria
- Finland
- France
- Germany
- Greece
- Ireland
- Italy
- Netherlands
- Norway
- Poland
- Portugal
- Romania
- Spain